46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000002744	2009/11/01	10/11/2009	Success of tocilizumab in RA patients with remission induction and sustained efficacy after discontinuation	Success of tocilizumab in RA patients with remission induction and sustained efficacy after discontinuation - Surprise study	rheumatoid arthritis	tocilizumab plus methotrexate tocilizumab	Keio University	NULL	Complete: follow-up complete	20years-old	75years-old	Male and Female	300	Not selected	Japan
2	NCT01120366 (ClinicalTrials.gov)	October 2009	6/5/2010	Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation	Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation	Rheumatoid Arthritis	Drug: Tocilizumab plus methotrexate;Drug: Tocilizumab	SURPRISE Study Group	NULL	Completed	20 Years	75 Years	Both	233	Phase 4	Japan
3	NCT00754572 (ClinicalTrials.gov)	February 2009	17/9/2008	A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis	A Single-arm, Open-label Study of the Safety and Reduction of Signs and Symptoms During Treatment With Tocilizumab in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: tocilizumab [RoActemra/Actemra];Drug: methotrexate	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	418	Phase 3	Argentina;Brazil;Chile;Colombia;Costa Rica;Ecuador;Mexico;Peru;Uruguay;Venezuela